Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis.

Trial Profile

Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2014

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Fracture; Osteoporosis
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Oct 2010 Results presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research.
    • 03 Nov 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top